Anandhan, Swetha http://orcid.org/0000-0001-9187-7921
Herbrich, Shelley
Goswami, Sangeeta
Guan, Baoxiang
Chen, Yulong
Macaluso, Marc Daniel
Jindal, Sonali http://orcid.org/0000-0002-3911-6815
Natarajan, Seanu Meena
Andrewes, Samuel W.
Xiong, Liangwen
Nagarajan, Ashwat
Basu, Sreyashi http://orcid.org/0000-0002-5028-3833
Tang, Derek Ng
Liu, Jielin
Min, Jimin
Maitra, Anirban http://orcid.org/0000-0001-7923-9978
Sharma, Padmanee http://orcid.org/0000-0003-4658-055X
Funding for this research was provided by:
Parker Foundation
Cancer Prevention and Research Institute of Texas
Article History
Received: 18 May 2023
Accepted: 21 May 2024
First Online: 10 July 2024
Competing interests
: P.S. reports consulting, advisory roles, and/or stocks/ownership for Achelois, Adaptive Biotechnologies, Affini-T, Apricity Health, BioAlta, BioNTech, Candel Therapeutics, Catalio, Dragonfly Therapeutics, Earli, Enable Medicine, Glympse, Forty-Seven Inc., Hummingbird, ImaginAb, JSL Health, Lava Therapeutics, Lytix Biopharma, Marker Therapeutics, PBM Capital, Phenomic AI, Polaris Pharma, Sporos, Time Bioventures, Trained Therapeutix, Two Bear Capital, and Venn Biosciences, and Polaris. A.M. earns royalties from Cosmos Wisdom Biotechnology, overseen by the UTMDACC Conflict of Interest Committee, and acts as a consultant for both Freenome and Tezcat Biotechnology. The remaining authors declare no competing interests.